1.Kessing, LV.Gender differences in patients presenting with a single depressive episode according to ICD-10. Soc Psychiatry Psychiatr Epidemiol 2005;40:197–201.
2.Levinson, DF.The genetics of depression: a review. Biol Psychiatry 2006;60:84–92.
3.Redrobe, JP, Dumont, Y, Quirion, R.Neuropeptide Y (NPY) and depression: from animal studies to the human condition. Life Sci 2002;71:2921–2937.
4.Husum, H, Vasquez, PA, Mathe, AA.Changed concentrations of tachykinins and neuropeptide Y in brain of a rat model of depression: lithium treatment normalizes tachykinins. Neuropsychopharmacology 2001;24:183–191.
5.Mathé, AA, Jimenez, PA, Theodorsson, E, Stenfors, C.Neuropeptide Y, neurokinin A and neurotensin in brain regions of Fawn-Hooded “depressed”, Wistar, and Sprague-Dawley rats. Effects of electroconvulsive stimuli. Prog Neuropsychopharmacol Biol Psychiatry 1998;22:529–546.
6.Jimenez-Vasquez, PA, Mathé, AA, Thomas, JD, Riley, EP, Ehlers, CL.Early maternal separation alters neuropeptide Y concentrations in selected brain regions in adult rats. Brain Res Dev Brain Res 2001;131:149–152.
7.Caberlotto, L, Fuxe, K, Overstreet, DH, Gerrard, P, Hurd, YL.Alterations in neuropeptide Y and Y1 receptor mRNA expression in brains from an animal model of depression: region specific adaptation after fluoxetine treatment. Brain Res Mol Brain Res 1998;59:58–65.
8.Heilig, M, Wahlestedt, C, Ekman, R, Widerlöv, E.Antidepressant drugs increase the concentration of neuropeptide Y (NPY)-like immunoreactivity in the rat brain. Eur J Pharmacol 1988;147:465–467.
9.Mathé, AA, Jousisto-Hanson, J, Stenfors, C, Theodorsson, E.Effect of lithium on tachykinins, calcitonin gene-related peptide, and neuropeptide Y in rat brain. J Neurosci Res 1990;26:233–237.
10.Stenfors, C, Theodorsson, E, Mathé, AA.Effect of repeated electroconvulsive treatment on regional concentrations of tachykinins, neurotensin, vasoactive intestinal polypeptide, neuropeptide Y, and galanin in rat brain. J Neurosci Res 1989;24:445–450.
11.Christensen, DZ, Olesen, MV, Kristiansen, H, Mikkelsen, JD, Woldbye, DPD.Unaltered neuropeptide Y (NPY)-stimulated [35S]GTPγS binding suggests a net increase in NPY signalling after repeated electroconvulsive seizures in mice. J Neurosci Res 2006;84:1282–1291.
12.Mikkelsen, JD, Woldbye, DPD.Accumulated increase in neuropeptide Y and somatostatin gene expression of the rat in response to repeated electroconvulsive stimulation. J Psychiatr Res 2006;40:153–159.
13.Husum, H, Mikkelsen, JD, Hogg, S, Mathé, AA.Mørk, A.Involvement of hippocampal neuropeptide Y in mediating the chronic actions of lithium, electroconvulsive stimulation and citalopram. Neuropharmacology 2000;39:1463–1473.
14.Redrobe, JP, Dumont, Y, Fournier, A, Quirion, R.The neuropeptide Y (NPY) Y1 receptor subtype mediates NPY-induced antidepressant-like activity in the mouse forced swimming test. Neuropsychopharmacology 2002;26: 615–624.
15.Heilig, M, Zachrisson, O, Thorsell, A et al. Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar depression: preliminary evidence for association with preproNPY gene polymorphism. J Psychiatr Res 2004;38:113–121.
16.Widerlöv, E, Lindstrom, LH, Wahlestedt, C, Ekman, R.Neuropeptide Y and peptide YY as possible cerebrospinal fluid markers for major depression and schizophrenia, respectively. J Psychiatr Res 1988;22:69–79.
17.Bannon, AW, Seda, J, Carmouche, M et al. Behavioral characterization of neuropeptide Y knockout mice. Brain Res 2000;868:79–87.
18.Sørensen, G, Lindberg, C, Wörtwein, G, Bolwig, TG, Woldbye, DPD.Different roles for neuropeptide Y Y1 and Y5 receptors in anxiety and sedation. J Neurosci Res 2004; 77:723–729.
19.Zhou, Z, Zhu, G, Hariri, AR et al. Genetic variation in human NPY expression affects stress response and emotion. Nature 2008;452:997–1001.
20.Karvonen, MK, Pesonen, U, Koulu, M et al. Association of a leucine(7)-to-proline(7) polymorphism in the signal peptide of neuropeptide Y with high serum cholesterol and LDL cholesterol levels. Nat Med 1998;4:1434–1437.
21.Okubo, T, Harada, S.Polymorphism of the neuropeptide Y gene: an association study with alcohol withdrawal. Alcohol Clin Exp Res 2001;25(6 Suppl):59S–62S.
22.Itokawa, M, Arai, M, Kato, S et al. Association between a novel polymorphism in the promotor region of the neuropeptide Y gene and schizophrenia in humans. Neurosci Lett 2003;347:202–204.
23.Mottagui-Tabar, S, Prince, JA, Wahlestedt, C, Zhu, G, Goldman, D, Heilig, M.A novel single nucleotide polymorphism of the neuropeptides Y (NPY) gene associated with alcohol dependence. Alcohol Clin Exp Res 2005;29: 702–707.
24.Niskanen, L, Karvonen, MK, Valve, R et al. Leucine 7 to proline 7 polymorphism in the neuropeptide Y gene is associated with enhanced carotid atherosclerosis in elderly patients with type 2 diabetes and control subjects. J Clin Endocrinol Metab 2000;85:2266–2269.
25.Niskanen, L, Voutilainen-Kaunisto, R, Terasvirta, M et al. Leucine 7 to proline 7 polymorphism in the neuropeptide Y gene is associated with retinopathy in type 2 diabetes. Exp Clin Endocrinol Diabetes 2000;108:235–236.
26.Lappalainen, J, Kranzler, HR, Malison, R et al. A functional neuropeptide Y Leu7Pro polymorphism associated with alcohol dependence in a large population sample from the United States. Arch Gen Psychiatry 2002;59:825–831.
27.Kauhanen, J, Karvonen, MK, Pesonen, U et al. Neuropeptide Y polymorphism and alcohol consumption in middle-aged men. Am J Med Genet 2000;93:117–121.
28.Sjöholm, lk, Melas, PA, Forsell, Y, Lavebratt, C.PreproNPY Pro7 protects against depression despite exposure to environmental risk factors. J Affect Disord 2009;118: 124–130.
29.Bosker, FJ, Hartman, CA, Nolte, IM et al. Poor replication of candidate genes for major depressive disorder using genome-wide association data. Mol Psychiatry 2011;16: 516–532.
30.Kessing, LV, Jørgensen, OS.Apolipoprotein E-ε4 frequency in affective disorder. Biol Psychiatry 1999;45: 430–434.
31.Mellerup, E, Bennike, B, Bolwig, T et al. Platelet serotonin transporters and the transporter gene in control subjects, unipolar patients and bipolar patients. Acta Psychiatr Scand 2001;103:229–233.
32.Haugboel, S, Pinborg, LH, Arfan, HM et al. Reproducibility of 5-HT2A receptor measurements and sample size estimations with [18F]altanserin PET using a bolus/infusion approach. Eur J Nucl Med Mol Imaging 2007;34:910–915.
33.Jørgensen, T, Borch-Johnsen, K, Thomsen, TF et al. A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99. Eur J Cardiovasc Prev Rehabil 2003;10:377–386.
34.Lindberg, C, Koefoed, P, Hansen, ES et al. No association between the – 399 C>T polymorphism of the neuropeptide Y gene and schizophrenia, unipolar depression or panic disorder in a Danish population. Acta Psychiatr Scand 2006; 113:54–58.
35.Koefoed, P, Hansen, TVO, Woldbye, DPD et al. An intron 1 polymorphism in the CCK-A receptor gene associated with schizophrenia in males. Acta Psychiatr Scand 2009; 120:281–287.
36.Hansen, T, Olsen, L, Lindow, M et al. Brain expressed microRNAs implicated in schizophrenia etiology. PLoS One 2007;12:e873.
37.Rehfeld, JF.Radioimmunochemical analysis of neuropeptides based on general characteristics of the analyte. Trends Analyt Chem 1989;8:102–106.
39.Ding, B.Distribution of the NPY 1128C allele frequency in different populations. J Neural Transm 2003;110: 1199–1204.
40.Domschke, K, Dannlowski, U, Hohoff, C et al. Neuropeptide Y (NPY) gene: impact on emotional processing and treatment response in anxious depression. Eur Neuropsychopharmacol 2010;20:301–309.
41.Mickey, BJ, Zhou, Z, Heitzeg, MM et al. Emotion processing, major depression, and functional genetic variation of neuropeptide Y. Arch Gen Psychiatry 2011;68:158–166.
42.Hegde, RS, Bernstein, HD.The surprising complexity of signal sequences. Trends Biochem Sci 2006;31:563–571.
43.Fitches, AC, Appleby, R, Lane, DA, De, SV, Leone, G, Olds, RJ.Impaired cotranslational processing as a mechanism for type I antithrombin deficiency. Blood 1998;92: 4671–4676.
44.Lanza, F, De La Salle, C, Baas, MJ et al. A Leu7Pro mutation in the signal peptide of platelet glycoprotein (GP)IX in a case of Bernard-Soulier syndrome abolishes surface expression of the GPIb-V-IX complex. Br J Haematol 2002;118:260–266.
45.Pidasheva, S, Canaff, L, Simonds, WF, Marx, SJ, Hendy, GN.Impaired cotranslational processing of the calcium-sensing receptor due to signal peptide missense mutations in familial hypocalciuric hypercalcemia. Hum Mol Genet 2005;14:1679–1690.
46.Ding, B, Kull, B, Liu, Z et al. Human neuropeptide Y signal peptide gain-of-function polymorphism is associated with increased body mass index: possible mode of function. Regul Pept 2005;127:45–53.
47.Mitchell, GC, Wang, Q, Ramamoorthy, P, Whim, MD. A common single nucleotide polymorphism alters the synthesis and secretion of neuropeptide Y. J Neurosci 2008;28: 14428–14434.
48.Kallio, J, Pesonen, U, Jaakola, U, Karvonen, MK, Helenius, H, Koulu, M.Changes in diurnal sympathoadrenal balance and pituitary hormone secretion in subjects with Leu7Pro. J Clin Endocrinol Metab 2003;88:3278–3283.
49.Jaakkola, U, Kuusela, T, Jartti, T et al. The Leu7Pro polymorphism of preproNPY is associated with decreased insulin secretion, delayed ghrelin suppression, and increased cardiovascular responsiveness to norepinephrine during oral glucose tolerance test. J Clin Endocrinol Metab 2005;90: 3646–3652.
50.Kallio, J, Pesonen, U, Kaipio, K et al. Altered intracellular processing and release of neuropeptides Y due to leucine 7 to proline 7 polymorphism in the signal peptide of preproneuropeptide Y in humans. FASEB J 2001;15: 1242–1244.
51.Heilig, M.The NPY system in stress, anxiety and depression. Neuropeptides 2004;38:213–224.
52.Ishida, H, Shirayama, Y, Iwata, M et al. Infusion of neuropeptide Y into CA3 region of hippocampus produces antidepressant-like effect via Y1 receptor. Hippocampus 2007;17:271–280.
53.Nikisch, G, Agren, H, Eap, CB, Czernik, A, Baumann, P, Mathé, AA.Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram. Int J Neuropsychopharmacol 2005;8: 403–410.